Professor of Medicine, Mayo Medical School
Hematology
Dr. Mark R. Litzow, MD
|
|
Give Review
Doctor Mark R. Litzow, MD is an expert in the field of Hematology. He studied medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He has 2 awards "America's Top Doctors" and "America's Top Doctors for Cancer". Mark R. Litzow, MD is a published MD as well. He has 100 publications published. The latest was: Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary. Mark Litzow accepts Medicare.
Publications
- Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case F...
- A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic Leukemia in old...
- Very late relapse of AML after allogeneic hematopoietic Cell transplantation is often extramedullary.
- ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and Acute myeloid leukemia undergoing HLA-matched per...
- Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
- Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem Cell transplant recipients.
- Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.
- Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
- Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole.
- Voriconazole exposure and the risk of cutaneous squamous Cell carcinoma in allogeneic hematopoietic stem Cell transplant patients.
- Relationship of Genetic Variation in the Serotonin Transporter Gene (SLC6A4) and Congenital and Acquired Cardiovascular Diseases.
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
- Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan or TBI.
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor Acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
- Philadelphia chromosome-negative Acute lymphoblastic leukemia: therapies under development.
- Immunosuppressive therapy of LGL Leukemia: prospective multicenter phase II study by the eastern cooperative oncology group (E5998).
- Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia.
- Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.
- Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucorMycosis in high-risk patients from 1995 to 2011: a comparison of eras immed...
- A nucleolin-DNMT1 regulatory axis in Acute myeloid leukemogenesis.
- Younger adults with Acute myeloid leukemia in remission for â¥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.
- Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow...
- Novel Antibody Therapy in Acute Lymphoblastic Leukemia.
- CD16xCD33 bispecific killer Cell engager (BiKE) activates NK Cells from MDS patients against primary MDS and MDSC CD33+ targets.
- Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program's System Capacity ...
- Reduced-intensity hematopoietic Cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow tran...
- Effect of post remission therapy prior to reduced intensity conditioning allogeneic transplantation for Acute myeloid leukemia in first complete remission.
- Progressive Multifocal Leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic Cell transplantation (HCT).
- Providing Personalized Prognostic Information for Adult Leukemia Survivors.
- Better Leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
- Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in Acute myeloid leukemia.
- The incidence of invasive fungal infections in neutropenic patients with Acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with vor...
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem Cell transplantation have superior outcomes compared with patients with multiple myelom...
- Unrelated donor allogeneic transplantation after failure of autologous transplantation for Acute myeloid leukemia: a study from the cibmtr.
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem Cell mobilization.
- Acute myeloid leukemia with translocation t(8;16) presents with features which mimic Acute promyelocytic leukemia and is associated with poor prognosis.
- Novel therapeutic approaches for Acute lymphoblastic leukemia.
- Therapy-related Acute promyelocytic leukemia (t-APL): Observations relating to APL pathogenesis and therapy.
- Long-term outcome of pomalidomide therapy in myelofibrosis.
- Long-term outcome of treatment with ruxolitinib in myelofibrosis.
- Peripheral blood lymphocyte and monocyte recovery and survival in Acute leukemia post myeloablative allogeneic hematopoietic stem cell transplant.
- Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study.
- Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup...
- Risk factors and outcome of pulmonary complications after autologous hematopoietic stem Cell transplant (HSCT).
- Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients.
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
- Autologous transplantation gives encouraging results for young adults with favorable-risk Acute myeloid leukemia but is not improved with gemtuzumab ozogamicin.
- Reducing the risk for transplantation-related mortality after allogeneic hematopoietic Cell transplantation: how much progress has been made?
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed Acute myeloid leukemia: a randomized, placebo-cont...
- Adult patients with Acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients register...
- Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for Acute myelogenous leukemia (AML) in adults.
- Hematopoietic stem-cell transplantation for Acute leukemia in relapse or primary induction failure.
- Second unrelated donor hematopoietic Cell transplantation for primary graft failure.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem Cell conditioning regimen in patients with multiple myeloma.
- Allogeneic transplantation for therapy-related myelodysplastic syndrome and Acute myeloid leukemia.
- Outcome of transplantation for myelofibrosis.
- Phase1/-2 study of Pomalidomide in myelofibrosis.
- T-cell Acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECO...
- Chronic myeloid Leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.
- Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive Acute lymphoblastic leukemia confirms superiority of allogeneic transpl...
- The graft-versus-Leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
- Evolving paradigms in the therapy of Philadelphia-chromosome-negative Acute lymphoblastic leukemia in adults.
- Risk factors for Acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid Leukemia.
- Autologous stem Cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Autologous stem Cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
- Autologous stem Cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
- Early lymphocyte recovery predicts superior survival after autologous stem Cell transplantation in non-Hodgkin lymphoma: a prospective study.
- In adults with standard-risk Acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remissi...
- Early peripheral blood blast clearance during induction chemotherapy for Acute myeloid leukemia predicts superior relapse-free survival.
- Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for Acute myeloid leukemia in first or second complete remission.
- Progress and strategies for patients with relapsed and refractory Acute myeloid leukemia.
- Allogeneic hematopoietic Cell transplantation in myelofibrosis with myeloid metaplasia.
- Hematologic manifestations of celiac Disease.
- MPL515 mutations in myeloproliferative and other Myeloid disorders: a study of 1182 patients.
- Lenalidomide therapy in myelofibrosis with Myeloid metaplasia.
- Imatinib resistance: obstacles and opportunities.
- Flow cytometric detection of circulating myeloma Cells before transplantation in patients with multiple myeloma: a simple risk stratification system.
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem Cell transplantation.
- A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allograf...
- Cyclophosphamide mobilization does not improve outcome in patients receiving stem Cell transplantation for multiple myeloma.
- Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for Acute myelogenous leukemia in first rem...
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in Myeloma patients treated with high-dose therapy.
- Successful treatment of scleromyxedema with autologous peripheral blood stem Cell transplantation.
- Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory Acute leukemia.
- Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.
- Comparison of Graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem Cell transplantation for patients with primary systemic amyloidosis.
- Peripheral blood stem cell transplantation in 16 patients with POEMS Syndrome, and a review of the literature.
- Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing Peripheral bl...
- Imatinib mesylate inhibits T-Cell proliferation in vitro and delayed-type hypersensitivity in vivo.
- Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem Cell transplantation: a case-control study.
- Spontaneous fusion of Cells between species yields transdifferentiation and retroviral transfer in vivo.
- Fatal coronary artery Disease after unrelated donor bone marrow transplantation.
Schools
University Of ChicagoThe Pritzker School Of Medicine
Mayo Clinic Rochester
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Mayo School of Graduate Medical Education -
University of Chicago Pritzker School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1871579672 | |
| NPPES Provider LastName | LITZOW | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1147.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 48.0 | |
| Percent Opioid Claims | 4.18 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871579672 |
| Last Name Of The Provider | LITZOW |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Morie A. Gertz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas E. Witzig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph P. Colgan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jocelin Huang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aminah Jatoi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Kyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sani H. Kizilbash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eapen K. Jacob, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameer A. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William G. Morice, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas M. Pisansky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Wiseman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle A. Elliott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald L. Richardson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Diasio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin C. Francis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Livia T. Hegerova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David B. Zhen, MD
This Doctor is OpenDoctor Recommended.
|